MELPHALAN IN THE TREATMENT OF MYELOMATOSIS.
作者信息
SPEED D E, GALTON D A, SWAN A
出版信息
Br Med J. 1964 Jun 27;1(5399):1664-9. doi: 10.1136/bmj.1.5399.1664.
Abstract
摘要
相似文献
1
MELPHALAN IN THE TREATMENT OF MYELOMATOSIS.
Br Med J. 1964 Jun 27;1(5399):1664-9. doi: 10.1136/bmj.1.5399.1664.
2
MYELOMATOSIS. A CLINICAL AND BIOCHEMICAL STUDY OF 105 CASES.
Acta Med Scand. 1964 Oct;176:509-24.
3
MYELOMA PROTEINS AND THE CLINICAL RESPONSE TO MELPHALAN THERAPY.
Science. 1965 Apr 16;148(3668):376-7. doi: 10.1126/science.148.3668.376.
4
EVALUATION OF MELPHALAN (NSC-8806) IN TREATMENT OF MULTIPLE MYELOMA.
Cancer Chemother Rep. 1964 Mar;36:25-34.
5
[Treatment of myelomatosis with melphalan and testosterone. Some biochemical changes in relation to therapeutics].
Folia Clin Int (Barc). 1966 Jul-Aug;16(7):339-41.
6
Alkeran (Melphalan) in the treatment of myelomatosis.
Acta Med Scand Suppl. 1966;445:187-93. doi: 10.1111/j.0954-6820.1966.tb02359.x.
7
Multiple myeloma in a dog.
J Am Vet Med Assoc. 1967 Feb 15;150(4):386-95.
8
COMPARISON OF CLINICAL FINDINGS AND HEMATOLOGIC CHANGES IN PATIENTS WITH CHRONIC ULCERATIVE COLITIS.
Am J Gastroenterol. 1963 Dec;40:601-10.
9
DOUBLE-BLIND STUDY OF CHLORDIAZEPOXIDE IN OBSTETRICS.
Obstet Gynecol. 1964 Oct;24:601-5.
10
[BEHAVIOR OF HEMATIC CRASIS IN PATIENTS AFFECTED BY GENITAL NEOPLASMS, SUBJECTED TO CHEMOTHERAPY WITH A NEW DERIVATIVE OF SARCOLYSIN].
Ann Ostet Ginecol. 1964 Jun;86:487-95.
引用本文的文献
1
Survival from multiple myeloma in England and Wales up to 2001.
Br J Cancer. 2008 Sep 23;99 Suppl 1(Suppl 1):S113-5. doi: 10.1038/sj.bjc.6604608.
2
CLINICAL TRIALS IN PROGRESS: LEUKAEMIA AND MULTIPLE MYELOMA.
Proc R Soc Med. 1965 Aug;58(8):630-2. doi: 10.1177/003591576505800831.
3
Effect of renal dysfunction in dogs on the disposition and marrow toxicity of melphalan.
Br J Cancer. 1981 Mar;43(3):330-4. doi: 10.1038/bjc.1981.52.
4
Plasma melphalan and prednisolone concentrations during oral therapy for multiple myeloma.
Cancer Chemother Pharmacol. 1982;9(1):57-60. doi: 10.1007/BF00296764.
5
Pharmacokinetics of melphalan in children following high-dose intravenous injection.
Cancer Chemother Pharmacol. 1983;10(3):212-6. doi: 10.1007/BF00255766.
6
Treatment of myelomatosis with fluoride.
Br Med J. 1967 Apr 15;2(5545):128.
7
The function of androgens and fluoride salts in the treatment of multiple myeloma.
Trans Am Clin Climatol Assoc. 1966;77:226-34.
8
Management of multiple myeloma.
Br Med J. 1969 Apr 19;2(5650):163-5. doi: 10.1136/bmj.2.5650.163.
9
The effect of 1-phenylalanine mustard on anti-globulin antibodies in multiple myeloma.
Clin Exp Immunol. 1971 Jan;8(1):91-100.
10
[The therapy of the paraproteinemias].
Blut. 1969 May;19(2):113-22. doi: 10.1007/BF01633092.
本文引用的文献
1
Treatment of multiple myeloma with urethan; experience with 66 cases over a 2 1/2 year period.
J Am Med Assoc. 1951 Oct 27;147(9):824-7. doi: 10.1001/jama.1951.03670260026008.
2
Multiple myelomatosis treated with a combination of urethane and an oral nitrogen mustard.
Blood. 1955 Mar;10(3):252-8.
3
MELPHALAN THERAPY IN MYELOMATOSIS.
Br Med J. 1964 Apr 4;1(5387):859-65. doi: 10.1136/bmj.1.5387.859.
4
CHEMOTHERAPY IN MYELOMATOSIS.
Proc R Soc Med. 1963 Aug;56(8):648-50. doi: 10.1177/003591576305600807.
5
Phase II trials of mitomycin C, AB-100, NSC-1026, L-sarcolysin, and meta-sarcolysin, in the treatment of multiple myeloma.
Cancer Chemother Rep. 1962 Feb;16:261-66.
6
Cyclophosphamide in Hodgkin's disease and related disorders.
Br Med J. 1960 Dec 24;2(5216):1837-40. doi: 10.1136/bmj.2.5216.1837.
7
[Clinical experiences with sarcolysin in neoplastic diseases].
Ann N Y Acad Sci. 1958 Apr 24;68(3):1128-32. doi: 10.1111/j.1749-6632.1958.tb42675.x.
Zotero 插件